Teva Pharmaceutical Industries Ltd

Teva’s $400 m partnership with Blackstone Life Sciences to push duvakitug into phase‑III showcases its shift from generics to high‑margin monoclonal antibodies, while investors pivot to financial ETFs amid market uncertainty.

Teva and Blackstone’s new partnership pushes duvakitug, a selective IL‑23 inhibitor, toward a fast‑track FDA/EMA review—offering potent UC/CD remission with a strong safety profile and new growth prospects for IBD biologics.

Teva Pharmaceutical Industries’ recent share rally reflects investor confidence in its robust generic, branded and API business, positioned for growth as global API demand expands.

Teva Pharmaceutical’s rising share price reflects strong generic & branded growth, API expertise, and cost‑saving impact on patients and payers.

Teva Pharmaceutical Industries Ltd. is poised for double‑digit earnings growth through 2026, boosted by a strong pipeline of branded generics, specialty drugs, and a winning patent ruling that secures market exclusivity in the β‑catenin oncology spa…

Teva partners with Will Forte for Huntington’s disease awareness, amid earnings release and a strategy to boost rare‑disease access while managing patent cliffs.

Teva’s CEO reveals a 2030 roadmap blending generics strength with biopharma innovation, plus a $500M Royalty Pharma deal to fast‑track vitiligo therapy, boosting growth prospects.

Teva’s CEO will reveal how the company balances low‑margin generics with high‑margin specialty drugs, tackling payer models, supply‑chain resilience, and patient access to drive future growth.

Teva’s credit‑rating upgrades reveal how its growth‑driven pivot, disciplined finance, and specialty‑medicine pipeline boost investor confidence and open new M&A horizons.

Teva’s European Commission approval of PONLIMSI and DEGEVMA, denosumab biosimilars, opens a high‑value bone‑health market, challenging branded therapies with lower pricing and boosting competitive dynamics.